FATE OF GLYCOSYLATED DEXTRANS AFTER INVIVO ADMINISTRATION

被引：26

作者：

VANSTEENKISTE, S ^{[1
]}

SCHACHT, E ^{[1
]}

DUNCAN, R ^{[1
]}

SEYMOUR, L ^{[1
]}

PAWLUCZYK, I ^{[1
]}

BALDWIN, R ^{[1
]}

机构：

[1] STATE UNIV GHENT,ORGAN CHEM LAB,B-9000 GHENT,BELGIUM

来源：

JOURNAL OF CONTROLLED RELEASE | 1991年 / 16卷 / 1-2期

关键词：

DEXTRAN; GLYCOSYLATION; TARGETING; RECEPTOR BLOCKING; IMMUNOTOXIN;

D O I：

10.1016/0168-3659(91)90033-A

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Polymers bearing galactose or mannose residues accumulate in the liver after intravenous administration to rat or mice. In this study dextrans carrying D-galactose residues were injected intravenously in rat. Their rates of blood clearance and body distribution were measured. D-Galactosylated polymers were cleared more rapidly in comparison with non-glycosylated control polymer. The former are more easily captured by the liver. Dextran substituted with tri-D-galactose units was cleared faster than mono-D-galactose substituted dextran. Introduction of FITC groups in dextran or D-galactosylated dextran (D.S.: 0.7%) resulted in a faster internalization by the liver. The effect of the galactose co-substituents was overridden by that of the FITC-moieties. D-Mannosylated dextran was evaluated as a blocker of liver D-mannose receptors. It was shown that co-administration of D-mannosylated dextran to i.v. administered ricin A immunotoxin significantly decreased the rate of blood clearance and liver uptake of the immunotoxin. Body distribution experiments carried out at 24 h indicated the liver blocking to be transient.

引用

页码：91 / 99

页数：9

共 42 条

[21]

Duncan, Kopececkova, Strohalm, Hume, Lloyd, Kopecek, Anticancer agents coupled to N-(2-hydroxypropyl) methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against L12101eukemia, Brit.J. Cancer, 57, pp. 147-155, (1988)

[22]

Schacht, Polysaccharide macromolecules as drug carriers, Polymers in Controlled Drug Delivery, pp. 152-171, (1987)

[23]

Schacht, Vercauteren, Vansteenkiste, Some aspects of the application of dextran in prodrug design, J. Bioact. Compat. Pol., 3, pp. 72-80, (1988)

[24]

Arturson, Granath, Thoren, Wallenius, The renal excretion of low molecular weight dextran, Acta Chir. Scand., 127, pp. 534-551, (1964)

[25]

Hint, Clinical use of rheomacrodex and macrodex, Acta Anaesth. Belg., 19, pp. 119-138, (1968)

[26]

Embleton, Byers, Lee, Scannon, Blackhall, Baldwin, Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines, Cancer Res., 46, pp. 5524-5528, (1986)

[27]

Byers, Pimm, Pawluczyk, Lee, Scannon, Baldwin, Biodistribution of ricin toxin A chain-monoclonal antibody 791T/36 immunotoxin and influence of hepatic blocking agents, Cancer Res., 47, pp. 5277-5283, (1987)

[28]

Pimm, Embleton, Perkins, Baldwin, In vivo localization of anti-osteogenic sarcoma 791 T monoclonal antibody in osteogenic sarcoma xenografts, Int. J. Cancer, 30, pp. 75-85, (1982)

[29]

de Belder, Granath, Preparation and properties of fluorescein-labeled dextrans, Carbohydrate Research, pp. 375-378, (1973)

[30]

Hupf, Wanek, O'Brien, Holland, Rapid radioiodination of rose bengal at room temperature, J. Nucl. Med., 19, pp. 525-529, (1978)

← 1 2 3 4 5 →